TipRanks on MSN

Insulet’s Omnipod SmartAdjust 2.0 trial wraps up: What investors should watch next

Insulet ($PODD) announced an update on their ongoing clinical study. Study Overview Insulet’s new study, officially titled “Safety and Efficacy of ...
MobiHealthNews

Insulet scores FDA greenlight for Omnipod 5 insulin delivery system

Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...
Monthly Prescribing Reference

FDA Clears Omnipod 5 Tubeless Insulin System for Diabetes Management

The Omnipod 5 System consists of a tubeless wearable Pod, the Omnipod 5 mobile app, and the Dexcom G6 Continuous Glucose Monitoring System. The Food and Drug Administration (FDA) has cleared the ...
Monthly Prescribing Reference

Omnipod 5 Tubeless Automated Insulin Delivery System Cleared for Younger Kids

The clearance was based on data from a single-arm multicenter clinical trial that evaluated the Omnipod 5 system in 80 children aged 2 to 5.9 years with type 1 diabetes. The Food and Drug ...
The American Journal of Managed Care

Omnipod 5 May Improve Psychosocial Outcomes for Patients With T1D, Study Suggests

Patients with type 1 diabetes (T1D) who used the Omnipod 5 Automated Insulin Delivery (AID) System saw significant improvements in psychosocial outcomes, including diabetes distress and hypoglycemic ...
FierceBiotech

FDA clears Insulet's Omnipod 5 closed-loop, tubeless insulin pump for adults and children

Insulet has secured an FDA clearance for its latest tubeless insulin pump, the Omnipod 5, a patch-like device capable of adjusting daily doses to changes in the wearer’s blood sugar levels. Designed ...
Nasdaq

Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev

Insulet Corporation’s PODD Omnipod and Omnipod DASH insulin management systems recently received FDA’s approval for their use with Eli Lilly and Company’s LLY Lyumjev (insulin lispro-aabc injection) ...
Business Wire

Insulet Announces FDA Clearance of Omnipod GO™, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...
Seeking Alpha

Insulet Launches Omnipod® 5 Automated Insulin Delivery System in Canada, a Revolutionary New Technology for People Living with Type 1 Diabetes Ages Two Years and Above

OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (PODD), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Omnipod 5 is now ...
TipRanks on MSN

Insulet’s new Omnipod M study targets the untapped type 2 diabetes pump market

Insulet ($PODD) announced an update on their ongoing clinical study. Study Overview: Insulet Corporation is running a new clinical study titled ...
Business Wire

Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
Seeking Alpha

Insulet raises full-year Omnipod revenue growth guidance to 29–30% as international momentum accelerates

Pease announced, "For the fourth quarter, we expect total Omnipod revenue growth of 27% to 30% and total company growth of 25% to 28%." She guided for fourth quarter U.S. Omnipod growth of 24% to 27% ...